A Phase 3 interventional study of TJO-002 and Latanoprost in Primary Open-angle Glaucoma and Ocular Hypertension, sponsored by Taejoon Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-09-04.
Sponsored by Taejoon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of — 3 open to participants now, 3 under way, 2 of them phase 3. Glaucoma, Open-Angle · Korea, Republic of.
Among the 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 13th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Kukje Pharma · Sites in Korea, Republic of
Ages 19+
Kukje Pharma · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 146 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 150 across the 15 interventional studies, 566 across the 6 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 21 have an industry lead sponsor. The 10 most frequent:
Taejoon Pharmaceutical Co., Ltd. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Taejoon Pharmaceutical Co., Ltd. has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma, Open-Angle with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07662759Phase 3Kukje Pharma[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension | 2027-03 |
| NCT07335211Phase 3Huons Co., Ltd.Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control administration groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female, age 19 or over
Any other Galucoma except POAG(ex, Closed anterior chamber angle, angle-closure glaucoma)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TJO-002
Drug: Latanoprost
Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
Change From Baseline in diurnal IOP at Week 12
After 12 weeks of administration of the drugs compare the therapeutic effectiveness between control drug and trial drug evaluated as the effect on reducing diurnal IOP.
Time frame: Baseline and Week 12
Change From Baseline in diurnal IOP at Week 8
After 8 weeks of administration of the drugs compare the therapeutic effectiveness between control drug and trial drug evaluated as the effect on reducing diurnal IOP.
Time frame: Baseline and Week 8
Ran from Apr 2016 to primary completion in Dec 2017, 20 months.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 20 months is below that.
Counting every sponsor, half of 49 studies reached it within 25 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taejoon Pharmaceutical Co., Ltd. →